Clinical pharmacokinetics and pharmacodynamics of linagliptin

Clinical Pharmacokinetics

Volumn 51, Issue 7, 2012, Pages 411-427

  Graefe Mody, Ulrike ^a   Retlich, Silke ^a   Friedrich, Christian ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

drug interactions; linagliptin; pharmacokinetics; pharmacology; type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; CYTOCHROME P450 3A4; DIGOXIN; DIPEPTIDYL PEPTIDASE IV; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLYCOPROTEIN P; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; MOXIFLOXACIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLACEBO; RIFAMPICIN; RITONAVIR; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; VILDAGLIPTIN; WARFARIN;

AGE DISTRIBUTION; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; BINDING AFFINITY; BODY MASS; BODY WEIGHT; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME INHIBITION; HUMAN; HYPERGLYCEMIA; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SEX DIFFERENCE; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; HUMANS; PURINES; QUINAZOLINES;

EID: 84861683713     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11630900-000000000-00000     Document Type: Review

References (73)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 countryyears and 2.7 million participants. Lancet 2011 Jul 2; 378 (9785): 31-40
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87 (1): 4-14
3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 [online]. Available from URL: http://www.cdc.gov/dia betes/pubs/pdf/ndfs-2007.pdf [Accessed 2010 Sep 10]
4. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999 Jun 2; 281 (21): 2005-12 (Pubitemid 29254858)
5. Defronzo RA. Banting lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009 Apr; 58 (4): 773-95
6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 Jan; 32 (1): 193-203
7. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011 Mar-Apr; 17 Suppl. 2: 1-53
8. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987 Dec 5; 2 (8571): 1300-4
9. Dupre J, Ross SA, Watson D, et al. Stimulation of insulin secretion by gastric inhibitory polypeptide inman. J Clin EndocrinolMetab 1973Nov; 37 (5): 826-8
10. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007 May; 132 (6): 2131-57 (Pubitemid 46711096)
11. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993 Jun 15; 214 (3): 829-35 (Pubitemid 23188160)
12. Tradjenta (linagliptin) prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc., 2010
13. Data on file, Boehringer Ingelheim, 2005
14. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010 Apr; 38 (4): 667-78
15. Data on file, Boehringer Ingelheim, 2006
16. Thomas L, EckhardtM, Langkopf E, et al. (R)-8-(3-amino-piperidin-1-yl)-7- but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008 Apr; 325 (1): 175-82 (Pubitemid 351439162)
17. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005 Oct; 54 (10): 2988-94 (Pubitemid 41401097)
18. Burkey BF, Hoffmann PK, Hassiepen U, et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008 Nov; 10 (11): 1057-61
19. Schurmann C, Linke A, Engelmann-Pilger K, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther. Epub 2012 Apr 4
20. Lambeir AM, Durinx C, Scharpe S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003 Jun; 40 (3): 209-94 (Pubitemid 36775376)
21. Fuchs H, Tillement JP, Urien S, et al. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 2009 Jan; 61 (1): 55-62
22. Retlich S, Withopf B, Greischel A, et al. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356): investigations in DPP-4 deficient and wildtype rats. Biopharm Drug Dispos 2009 Nov; 30 (8): 422-36
23. Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 2009 Jul; 30 (5): 229-40
24. Hü ttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008 Oct; 48 (10): 1171-8
25. Retlich S, Duval V, Ring A, et al. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet 2010 Dec 1; 49 (12): 829-40
26. Graefe-Mody U, Giessmann T, Ring A, et al. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther 2011 Aug; 33 (8): 1096-103
27. Sarashina A, Sesoko S, Nakashima M, et al. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther 2010 Jun; 32 (6): 1188-204
28. Friedrich C, Glund S, Lionetti D, et al. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes [abstract]. J Clin Pharmacol 2011 Sep; 51 (9): 1336
29. Heise T, Graefe-Mody EU, Huttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009 Aug; 11 (8): 786-94
30. Forst T, Uhlig-Laske B, Ring A, et al. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011 Jun; 13 (6): 542-50
31. Horie Y, Kanada S, Watada H, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clin Ther 2011 Jul; 33 (7): 973-89
32. Retlich S, Duval V, Graefe-Mody U, et al. Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol 2010 Aug; 50 (8): 873-85
33. Januvia (sitagliptin) prescribing information. Whitehouse Station (NJ): Merck and Co. Inc., 2010
34. Onglyza (saxagliptin) prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2010
35. Galvus (vildagliptin) prescribing information. Camberley, Surrey, UK: Novartis Pharmaceuticals UK Ltd, 2010
36. Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008 Mar; 30 (3): 513-27 (Pubitemid 351492530)
37. Data on file, Boehringer Ingelheim, 2010
38. Trajenta (linagliptin). Summary of product characteristics. Ingelheim: Boehringer Ingelheim International GmbH, 2011
39. Trazenta (linagliptin) prescribing information. Tokyo: Nippon Boehringer Ingelheim Co., Ltd, 2011
40. Finding a safe and effective dose of linagliptin in paediatric patients with type 2 diabetes [ClinicalTrials.gov identifier NCT01342484]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.cli nicaltrials.gov [Accessed 2011 Dec 16]
41. Efficacy and safety of linagliptin in elderly patients with type 2 diabetes [ClinicalTrials.gov identifier NCT01084005]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clini caltrials.gov [Accessed 2011 Dec 16]
42. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ 1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005 Jan 13; 48 (1): 141-51 (Pubitemid 40105255)
43. Data on file, Boehringer Ingelheim, 2009
44. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011 Mar; 13 (3): 258-67
45. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2010 Jan; 13 (1): 65-74
46. Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011 Nov; 28 (11): 1352-61
47. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012 Apr; 14 (4): 348-57
48. Monami M, Iacomelli I, Marchionni N, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010 May; 20 (4): 224-35
49. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006 Jan; 28 (1): 55-72 (Pubitemid 43254990)
50. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; (2): CD006739
51. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, noninferiority trial. Diabetes Obes Metab 2011 Feb; 13 (2): 160-8
52. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010 Sep; 12 (9): 780-9
53. Gallwitz B, Rosenstock R, Rauch T, et al. Two-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, active controlled, non-inferiority trial. Lancet. In Press
54. Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care 2011 May; 34 Suppl. 2: S264-71
55. Ring A, Port A, Graefe-Mody EU, et al. The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. Br J Clin Pharmacol 2011 Jul; 72 (1): 39-50
56. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011 Oct; 13 (10): 939-46
57. Graefe-Mody EU, Rose P, Ring A, et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. Epub 2012 Jan 13
58. Friedrich C, Emser A, Woerle H-J, et al. Renal impairment has no relevant effect on long-term exposure of linagliptin in patients with type 2 diabetes mellitus [poster]. Diabetes 2011 Jul; 60 Suppl. 1: A303
59. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009 Nov; 31 (11): 2608-17
60. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med 2011 May; 123 (3): 133-43
61. Sloan L, Newman J, Sauce C, et al. Safety and efficacy of linagliptin in type 2 diabetes patients with severe renal impairment [poster]. Diabetes 2011 Jul; 60 Suppl. 1: A114
62. Newman J, McGill J, Patel S, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment [poster]. Diabetologia 2011; 54 Suppl. 1: S108
63. Graefe-Mody EU, Padula S, Ring A, et al. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009 Aug; 25 (8): 1963-72
64. Graefe-Mody U, Rose P, Ring A, et al. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab Pharmacokinet 2011; 26 (2): 123-9
65. Graefe-Mody EU, Jungnik A, Ring A, et al. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. Int JClin PharmacolTher 2010Oct; 48 (10): 652-61
66. Graefe-Mody U, Huettner S, Stahle H, et al. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther 2010 Jun; 48 (6): 367-74
67. Friedrich C, Ring A, Brand T, et al. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet 2011 Mar; 36 (1): 17-24
68. Food and Drug Administration. Guidance for Industry. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). September 2006 [online]. Available from URL: http://www.fda.gov/down loads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM 072101.pdf [Accessed 2011 Oct 7]
69. Graefe-Mody EU, Brand T, Ring A, et al. Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Int J Clin Pharmacol Ther 2011 May; 49 (5): 300-10
70. Friedrich C, Port A, Ring A, et al. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multipledose study. Clin Drug Investig 2011; 31 (9): 643-53
71. de Heer J, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007 Feb; 56 (2): 438-43
72. Johansen OE, Neubacher D, von EynattenM, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012 Jan 10; 11: 3
73. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes [ClinicalTrials.gov identifier NCT01243424]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Dec 16]